ライフサイエンスコーパス: New York

1 LY gained in California to $817,753 /QALY in New York).

2 counters (80% EU, 90% Massachusetts, and 53% New York).

3 roportions of private insurance (44% EU, 67% New York).

4 AR, LVAD, and TAVR recipients in Ontario and New York.

5 patients from Alabama, and 14 patients from New York.

6 nvolving 15 Head Start preschools in Harlem, New York.

7 control measures introduced in the state of New York.

8 om 150 PWID from 3 OAT clinics in the Bronx, New York.

9 uburn, AL; and 3) Broome and Tioga Counties, New York.

10 esided in the Williamsburg area of Brooklyn, New York.

11 plant surgeon and transplant hepatologist in New York.

12 quantified in samples from 111 lakes across New York.

13 involved 15 Head Start preschools in Harlem, New York.

14 nder women, in Bangkok, Thailand and Harlem, New York.

15 dmission to the Mount Sinai Health System in New York.

16 ) in transplant recipients in New York City, New York.

17 icide sensitivity for isolates identified in New York.

18 from a randomized trial conducted in Bronx, New York.

19 equences of hemagglutinin for influenza from New York.

20 ents seen in the United States (Mount Sinai, New York), 128 patients from Sweden, and 208 from Iran r

21 t LTs were performed in California (47%) and New York (18%).

22 IDEAL conferences held in Oxford (2016) and New York (2017), this article updates and extends the ID

23 The Adirondack Mountain region of New York, a historical hotspot for atmospheric sulfur an

24 The New York African Burial Ground (NYABG) is the country's

25 36 LVAD recipients from Ontario and 686 from New York (age, 57.4 versus 57.7 years; P=0.80): 1708 TAV

26 8 TAVR recipients from Ontario and 4838 from New York (age, 83.1 versus 83.1; P=1.0).

27 New York and California were the 2 states with the great

28 ency departments and acute care hospitals in New York and Florida between 2005 and 2015.

29 All-payer claims data from the 2014 New York and Florida Healthcare Cost and Utilization Pro

30 or cancer were identified from the 2007-2013 New York and Florida Healthcare Cost and Utilization Pro

31 In New York and London, individuals in high-income occupati

32 Segregation was highest in New York and lowest in Tokyo.

33 percutaneous coronary intervention outcomes (New York and Massachusetts) versus neighboring states wi

34 Sensitivity analyses were performed for New York and Medicare patients to assess for influence o

35 For example, for New York and Michigan, isolation of persons exposed to t

36 ted geographically, with the top two states (New York and New Jersey) each experiencing over 10 exces

37 Results were unchanged when excluding New York and New Jersey.

38 available FR exposures of 78 cats (>=7 y) in New York and Oregon using gas chromatography-mass spectr

39 eviewed the donor charts of unused hearts in New York and Vermont (UNOS Region 9).

40 rica isolates from bovine and human hosts in New York and Washington states to understand host- and g

41 gained in Florida to $11,265/QALY gained in New York) and least cost-effective among people with dia

42 12) for 6 states, representing Northeastern (New York) and Southeastern (Florida, Georgia, Kentucky,

43 include several major cities such as Miami, New York, and Boston, with a total population over 13 mi

44 less or incarcerated in California, Florida, New York, and Texas - states where more than half of US

45 ia, Colorado, Illinois, Kentucky, Minnesota, New York, and Texas), one county, and one academic medic

46 A 400-isolate collection from New York apple orchards were morphologically assorted to

47 bility, but only among US-born women in this New York-based population.

48 received EVAR, LVAD, or TAVR in Ontario and New York between 2012 and 2015.

49 collected 370 unique donors enrolled in the New York Blood Center Convalescent Plasma Program betwee

50 formatics teams of the NYU Abu Dhabi and NYU New York Centers for Genomics and Systems Biology.

51 altimore (MD), Los Angeles (CA), Miami (FL), New York City (NY), and Seattle (WA).

52 occur in major US metropolitan regions like New York City (NY), Los Angeles (CA), Atlanta (GA), and

53 ents with COVID-19 have been hospitalised in New York City (NY, USA) as of April 28, 2020.

54 In 2014, New York City (NYC) committed to reduce GHG emissions by

55 New York City (NYC) experienced a surge of COVID-19 case

56 GROUNDFrom March 2, 2020, to April 12, 2020, New York City (NYC) experienced exponential growth of th

57 New York City (NYC) has emerged as one of the epicenters

58 universal testing and treatment policies in New York City (NYC).

59 center cohort study including 7 hospitals in New York City and Milan of hospitalized patients with la

60 ncrease PrEP prescribing and related care in New York City and New England.

61 health care workers and first responders in New York City and the Detroit metropolitan area with his

62 Given the high prevalence of asthma in the New York City area, our objective was to determine wheth

63 of 2019, a measles outbreak occurred in the New York City area, with a total of 649 cases reported.

64 ized patients with confirmed COVID-19 in the New York City area.

65 An outbreak of measles in New York City began when one unvaccinated child returned

66 open cohort of patients in a MAT program in New York City between 1 January 2013 and 31 December 201

67 confirmed COVID-19 in our hospital system in New York City between 12 March and 23 April 2020.

68 of 5 Mount Sinai Health System hospitals in New York City between February 27 and June 26, 2020.

69 of 5 Mount Sinai Health System hospitals in New York City between February 27, 2020, and April 12, 2

70 patients with COVID-19 at a single center in New York City between March and June of 2020.

71 e, we report the prevalence of SARS-CoV-2 in New York City boroughs inferred using tests administered

72 ristics and hospital bed capacities of the 5 New York City boroughs, and evaluates whether difference

73 In a predominantly hospitalized New York City cohort, elderly patients are at highest mo

74 n at the 90th to the 50th percentiles of the New York City density, and closed 5% to 25% of outlets w

75 The total direct cost to the New York City Department of Health and Mental Hygiene wa

76 ta suggest that SARS-CoV-2 was introduced in New York City earlier than previously documented and des

77 aly from April 6 to May 9 and over 66,000 in New York City from April 17 to May 9.

78 New York City has been described as the epicenter of the

79 ut COVID-19 who were hospitalized in a large New York City health system and compared them with a his

80 as patients of mixed race/ethnicity within a New York City health system.

81 We used the New York City HIV Surveillance Registry to determine HIV

82 sease and toxic shock syndrome admitted to a New York City hospital in late April and early May 2020.

83 avirus disease 2019 (COVID-19) presenting to New York City hospitals in March 2020 led to a sharp inc

84 Four New York City hospitals that are part of the same health

85 clinical transthoracic echocardiography at 3 New York City hospitals were studied; images were analyz

86 impact of coronavirus disease (COVID-19) on New York City hospitals, our institution prepared for an

87 14 without cancer who were admitted to three New York City hospitals.

88 valence among pregnant women delivering in 2 New York City hospitals.

89 in patients hospitalized with COVID-19 in 4 New York City hospitals.

90 uito-borne arbovirus-entered the USA through New York City in 1999 and spread to the contiguous USA w

91 ion services co-located at clinical sites in New York City intended to maximize credits and reduce po

92 among patients hospitalised with COVID-19 in New York City is common and associated with a high frequ

93 vember 2017, in response to a lawsuit from a New York City lung transplant candidate, an emergency ch

94 f 864 SARS-CoV-2 sequences from cases in the New York City metropolitan area during the COVID-19 outb

95 ospitalizations differ substantially between New York City neighborhoods.

96 tality rates between 2007 and 2017 among all New York City residents living with HIV and aged 13+ by

97 at a multicenter network of hospitals within New York City to evaluate order volume, positivity rate,

98 himpanzee who was raised during the 1930s in New York City to live much like a human, including by ha

99 The first case of COVID-19 in New York City was officially confirmed on 1 March 2020 f

100 lt patients at an academic medical center in New York City who had S. aureus bloodstream infections b

101 among homeless adults who were eligible for New York City's supportive housing program in 2007-2012.

102 al 19.1-43.7; Seattle) and 50.1% (41.5-58.0; New York City) by 2030, at ICERs ranging from cost-savin

103 In three US cities (Baltimore, Chicago, New York City), we use community garden networks as a mo

104 nfants from the State of New York (excluding New York City).

105 ) emissions, we find a +22% overestimate for New York City, a -21% underestimate in Toronto, and good

106 During March in New York State, outside of New York City, a total of 47 326 persons tested positive

107 for Atlanta, Baltimore, Los Angeles, Miami, New York City, and Seattle, we assessed the value of imp

108 igation measures in Wuhan, China, Italy, and New York City, from January 23 to May 9, 2020, we illust

109 confirmed brucellosis cases were reported in New York City, leading to 10 Brucella exposure risk even

110 Here, using data for New York City, London and Tokyo, we reframe and answer t

111 ts with COVID-19 admitted to 12 hospitals in New York City, Long Island, and Westchester County, New

112 scharges from a large hospital system in the New York City, New York metropolitan area, between Janua

113 rtality (18-28%) in transplant recipients in New York City, New York.

114 easurements of various VOCs are reported for New York City, Pittsburgh, Chicago, and Denver.

115 odels for Hubei, China; Lombardy, Italy; and New York City, United States.

116 In two field studies in New York City, we make critical information salient by r

117 als screened at Mount Sinai Health System in New York City, we report that the vast majority of infec

118 eropositivity among health care workers at a New York City-based health system by age, sex, race, cou

119 ning COVID-19 at The Mount Sinai Hospital in New York City.

120 ng children led to an outbreak of measles in New York City.

121 rch 30 to April 30, 2020 at two hospitals in New York City.

122 les from patients at Mount Sinai Hospital in New York City.

123 205 patients from a tertiary care center in New York City.

124 tures may influence active transportation in New York City.

125 agent-based model of the adult population in New York City.

126 g investigations of the C. auris outbreak in New York City.

127 nagement within a syringe service program in New York City.

128 during the first 3 weeks of the outbreak in New York City.

129 Donald was born October 1, 1949 in New York City.

130 r 31, 2019, at a quaternary care hospital in New York City.

131 bation or death at a large medical center in New York City.

132 ARS-CoV-2 from a network of 53 facilities in New-York City.

133 igher utilization of EVAR, LVAD, and TAVR in New York compared to Ontario.

134 sing spondylitis was defined by the modified New York criteria in 1984.

135 e ankylosing spondylitis, fulfilled modified New York criteria, were previously untreated with biolog

136 te at the Icahn School of Medicine (PrIISM), New York, describe their contribution to the global rese

137 ecipients in Ontario were female compared to New York (EVAR, 15.8% versus 22.1% female; P<0.001; TAVR

138 10) of mothers and infants from the State of New York (excluding New York City).

139 A subset of Fire Department of New York firefighters demonstrated resistance to subsequ

140 Utilization was significantly higher in New York for all procedures: EVAR (12.8 procedures per-1

141 (Crassostrea virginica Gmelin) collected in New York for morphological and molecular comparison.

142 ed from patients in the Lower Hudson Valley, New York, from 2014 to 2018 were examined for rhinovirus

143 arge proportion of Medicaid (75%) and EU and New York having large proportions of private insurance (

144 an LVOT gradient of 50 mm Hg or greater and New York Heart Association (NYHA) class II-III symptoms

145 th left ventricular ejection fraction <=40%, New York Heart Association (NYHA) class II-III, estimate

146 lder age (HR 1.04; 95% CI 1.01-1.06), higher New York Heart Association (NYHA) functional class (HR 1

147 g the following enrollment criteria: current New York Heart Association (NYHA) functional class III o

148 At baseline, 83% were in New York Heart Association (NYHA) functional class III t

149 New York Heart Association (NYHA) functional class IV HF

150 eptor neprilysin inhibitor (ARNI) treatment, New York Heart Association (NYHA) functional class, race

151 benefit varied according to HF etiology and New York Heart Association (NYHA) functional class: isch

152 ed 40 patients (50% anemic) with chronic HF, New York Heart Association class >=II, left ventricular

153 aturation (6.8%; 95% CI, 2.7-10.8; P=0.002), New York Heart Association class (-0.23; 95% CI, -0.46 t

154 tral regurgitation grade <=1 (+) and were in New York Heart Association class I to II (81.7%).

155 Sixty-one New York Heart Association class I to II patients with H

156 The majority of patients (89%) were in New York Heart Association class I-II at 6 months.

157 ial improvement in heart failure symptoms to New York Heart Association class I/II (96% in SM and 90%

158 ic volume (-8.0 mL versus -12.7 mL), whereas New York Heart Association class I/II was found in 80.1%

159 oderate or greater triscuspid regurgitation, New York Heart Association class II or higher, and who w

160 tore sinus rhythm) and dyspnea classified as New York Heart Association class II or higher.

161 Patients (N = 305) with New York Heart Association class II or III HFpEF with el

162 ve patients with chronic exertional dyspnea (New York Heart Association class II to IV) and ejection

163 New York Heart Association class II was associated with

164 ed 5050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an

165 ricular ejection fraction 45% or higher with New York Heart Association class II-III symptoms, within

166 ry (PA) sensor is approved for patients with New York Heart Association Class III heart failure (HF)

167 ss 104 centers within the United States with New York Heart Association class III HF and a prior HFH

168 (98%), with clinical HF characterized by 65% New York Heart Association Class III or IV, nearly all o

169 ts with single left-sided native VHD were in New York Heart Association class III or IV.

170 s ~6 times more preferred than a change from New York Heart Association class III to II.

171 r ejection fraction 33+/-11%, and 25% having New York Heart Association class III to IV; 650 patients

172 ical functioning equivalent to a change from New York Heart Association class IV to III was ~6 times

173 ught to study the relationship between LVEF, New York Heart Association class on presentation, and th

174 Left ventricular function and New York Heart Association class were assessed at baseli

175 (70%) or neurocardiogenic syncope 25 (30%), New York Heart Association class<II and absence of signi

176 here was no difference between the groups in New York Heart Association class, 6-minute walk distance

177 e in postexercise LV outflow tract gradient, New York Heart Association class, peak oxygen consumptio

178 peak oxygen consumption with no worsening of New York Heart Association class.

179 =1.5 mL/kg/min and reduction of at least one New York Heart Association class; or (2) an improvement

180 6 months/1 year, 83% of the patients were in New York Heart Association classes I/II.

181 g 9 variables (QRS morphology, QRS duration, New York Heart Association classification, left ventricu

182 Ablation, multivalve surgery, and New York Heart Association functional (NYHA) functional

183 ocarditis, aortic valve re-intervention, and New York Heart Association functional class >=II.

184 showed a protective effect of ASD closure on New York Heart Association functional class and on right

185 more likely to experience an improvement in New York Heart Association functional class and were 20%

186 ed from 24+/-7% to 38+/-10% ( P<0.0001), and New York Heart Association functional class changed from

187 At first evaluation, 93% of patients were in New York Heart Association functional class I or II.

188 /kg per minute, and 92% of participants were New York Heart Association functional class I.

189 Patients in New York Heart Association functional class II or greate

190 ible if they were aged 21 years or older, in New York Heart Association functional class II or higher

191 Eligible adults with oHCM and New York Heart Association Functional Class II or III ar

192 New York Heart Association functional class II symptoms

193 ATTR-CM, New York Heart Association functional class II to III su

194 diac effects of empagliflozin in patients in New York Heart Association functional class II to IV wit

195 Eligibility criteria in PARADIGM-HF included New York Heart Association functional class II to IV, le

196 Patients in New York Heart Association functional class II to IV, wi

197 se II study in adults with symptomatic nHCM (New York Heart Association functional class II/III), lef

198 At diagnosis, 92% were in New York Heart Association functional class III or IV.

199 atients with >=Mod TR were more likely to be New York Heart Association functional class III/IV (p <

200 New York Heart Association functional class improved, wi

201 Echocardiographic parameters and New York Heart Association functional class were assesse

202 10.0 years) and adjusting for demographics, New York Heart Association functional class, aortic valv

203 atient characteristics: age, sex, ethnicity, New York Heart Association functional class, ischemic et

204 emained significant after adjusting for sex, New York Heart Association functional class, right ventr

205 o 40% less likely to experience worsening of New York Heart Association functional class, with statis

206 atients (48%) achieved clinical stability in New York Heart Association functional classes I/II with

207 eloped refractory heart failure to disabling New York Heart Association functional classes III/IV (5.

208 In the ablation group, New York Heart Association I/II patients at the time of

209 ection fraction 32.5% (9.8%), and 81 (77.1%) New York Heart Association II and 24 (22.9%) New York He

210 Over 7.7 median years of follow-up, New York Heart Association III-IV heart failure was more

211 New York Heart Association II and 24 (22.9%) New York Heart Association III.

212 l as heart failure symptoms at presentation (New York Heart Association III/IV: 18.1% versus 15.8% ve

213 Patients with New York Heart Association III/IVa symptoms despite medi

214 with 42.7% of controls experienced >=1 class New York Heart Association improvement (P<0.001).

215 Changes in New York Heart Association were a secondary end point.

216 is equally safe and improves peak VO(2) and New York Heart Association.

217 14; and 2) validate this algorithm using the New York HIV surveillance system.

218 inal 5000 HIV-infected population of Western New York HIV/AIDS, Referral Center at Erie County Medica

219 cal Centers (VAMC) (Atlanta, Georgia; Bronx, New York; Houston, Texas; and Los Angeles, California) a

220 one and ST5/ST225-MRSA-II, Rhine-Hesse EMRSA/New York-Japan Clone in our setting was detected.

221 Brazil, three international airports-Miami, New York-John F.

222 ven states (California, Colorado, Minnesota, New York, Kentucky, Illinois, and Texas); one county (Ma

223 study on OMP occurrence in surface waters of New York lakes.

224 The 2013 New York mandate that all hospitals develop and implemen

225 5 EVAR recipients from Ontario and 6236 from New York (mean age 74.6 versus 74.5 years; P=0.61): 136

226 op an algorithm that could identify PLWDH in New York Medicaid data from 2006-2014; and 2) validate t

227 In March 2020, the greater New York metropolitan area became an epicenter for sever

228 large hospital system in the New York City, New York metropolitan area, between January 1st, 2006 an

229 nting 88.2% of patients with COVID-19 in the New York metropolitan region.

230 n Causal Inference; Oxford University Press, New York, New York), rather than the paper on placental

231 Florida, Kentucky, Massachusetts, Michigan, New York, North Carolina, Tennessee, and Washington from

232 indings from an ongoing C. auris outbreak in New York (NY) from August 2016 through 2018.

233 program at New York-Presbyterian Hospital in New York, NY rapidly and comprehensively transitioned it

234 ce was monitored electronically (AdhereTech, New York, NY) during the 7-month program.

235 avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), a C5 inhibitor, were assessed in particip

236 travel to either Europe (odds ratio, 6.1) or New York (odds ratio, 32.9).

237 P<0.001); and TAVR (6.6 in Ontario, 14.3 in New York; P<0.001).

238 P<0.001); LVAD (0.3 in Ontario versus 1.3 in New York; P<0.001); and TAVR (6.6 in Ontario, 14.3 in Ne

239 -100 000 adults per-year in Ontario, 20.2 in New York; P<0.001); LVAD (0.3 in Ontario versus 1.3 in N

240 he New York State Health Department from the New York Patient Occurrence Reporting and Tracking progr

241 2013, and November 30, 2015, who were in the New York PCI registry and other hospital databases were

242 with 1.2 (EU), 10 (Massachusetts), and 0.6 (New York) per 1,000 adults based on 2010 census data.

243 for SARS-CoV-2 with known blood type in the New York Presbyterian (NYP) hospital system to assess th

244 In late March 2020, New York Presbyterian Hospital centralized all of its in

245 The New York Presbyterian Hospital-Weill Cornell Medicine PI

246 Within 1 week, the PICU at New York Presbyterian Hospital-Weill Cornell Medicine tr

247 ted at Morgan Stanley Children's Hospital of New York-Presbyterian during April and May 2020.

248 g the pandemic, the heart failure program at New York-Presbyterian Hospital in New York, NY rapidly a

249 sitive for COVID-19 and were admitted to two New York-Presbyterian hospitals between March 3 and May

250 nference; Oxford University Press, New York, New York), rather than the paper on placental abruption,

251 Higher utilization of EVAR and TAVR in New York relative to Ontario increased substantially wit

252 In California and New York, respectively, overnight EV charging produces ~

253 New York's cardiac registry identified 63,402 multivesse

254 Data from multivessel disease patients in New York's cardiac surgery and percutaneous coronary int

255 ryngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)

256 Why do people in New York seem to walk faster than other cities?

257 In New York, SIR for Broome and Tioga counties were 0.93 an

258 Using New York State (NYS) and its dairy cattle farms as a mod

259 ibiotic prescribing practices in ESRD across New York State (NYS).

260 tes before the regulations, and was 22.0% in New York State and 19.1% in the control states after the

261 ed 30-day in-hospital mortality was 26.3% in New York State and 22.0% in the control states before th

262 f adult patients hospitalized with sepsis in New York State and in 4 control states (Florida, Marylan

263 isystem inflammatory syndrome in children in New York State coincided with widespread SARS-CoV-2 tran

264 Department of Public Health (statewide), and New York State Department of Health (11 counties).

265 The New York State Department of Health (NYSDOH) established

266 In collaboration with the New York State Department of Health, our hospital develo

267 New York State faced a substantial and increasing COVID-

268 conducted in adult patients with obesity in New York state from 2006 to 2012.

269 As of 10 April 2020, New York State had 180,458 cases of severe acute respira

270 l associated hospitalizations and mortality; New York State has emerged as the national epicenter.

271 ce Company from closed case files and by the New York State Health Department from the New York Patie

272 014 and 2) validate this algorithm using the New York State HIV surveillance system.

273 Beginning in 2013, New York State implemented regulations mandating that ho

274 op an algorithm that could identify PLWDH in New York State Medicaid data from 2006-2014 and 2) valid

275 % CI, -$681 to $7,934) more than expected in New York State relative to control states.

276 f the regulations decreased significantly in New York State relative to the control states (P = .02 f

277 Hospitals in New York State reported cases of Kawasaki's disease, tox

278 We evaluated the effects of the 2013 New York State sepsis regulations on the costs of care f

279 ptember 30, 2015) implementation of the 2013 New York State sepsis regulations.

280 Mean unadjusted costs per hospitalization in New York State were $42,036 +/- $60,940 in the pre-regul

281 y 1996 and December 2014 were reviewed using New York State's mandatory hospital discharge database.

282 PM(2.5) concentrations at six urban sites in New York State, a case-crossover design, and conditional

283 nd test results during the month of March in New York State, along with risk factors, outcomes, and h

284 In New York State, mandated protocolized sepsis care was as

285 During March in New York State, outside of New York City, a total of 47

286 EVAR, LVAD, and TAVR in Ontario, Canada, and New York State, United States.

287 tick in the United States, which occurred in New York State.

288 osts in patients hospitalized with sepsis in New York State.

289 's use of Twitter diverts crucial media (The New York Times and ABC News) from topics that are potent

290 ticles published about climate change in The New York Times, The Wall Street Journal, and USA Today f

291 nd May 31, 2017, from Children's Hospital of New York, to predict chronological age.

292 orecker in the Department of Microbiology at New York University (NYU), she embarked on her research

293 mendations in 2016, and at the tenth IWWM in New York, USA (October, 2018) an international consensus

294 Reichert Ophthalmic Instruments Inc, Depew, New York, USA).

295 ield dataset across 500+ parcels in Buffalo, New York, USA.

296 2% of isolates from 7 hospitals in Brooklyn, New York, were nonsusceptible to delafloxacin.

297 19 (COVID-19) caused more infections than in New York, where there have been over 26 500 infections.

298 ation on endangered Atlantic Sturgeon in the New York Wind Energy Area (NY WEA), a future offshore de

299 Among patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquin

300 k City, Long Island, and Westchester County, New York, within the Northwell Health system.